Ifp Advisors, Inc Savara Inc Transaction History
Ifp Advisors, Inc
- $3.28 Billion
- Q2 2025
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding SVRA
# of Institutions
124Shares Held
164MCall Options Held
38.7KPut Options Held
0-
Nea Management Company, LLC Timonium, MD24.5MShares$94.9 Million4.63% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA17.6MShares$68.3 Million12.04% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$48 Million5.75% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$44.5 Million1.38% of portfolio
-
Vestal Point Capital, LP New York, NY11MShares$42.7 Million1.32% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $442M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.